Photo of Andrew Kline

In July 2021, three Democratic senators—Cory Booker, Ron Wyden, and Majority Leader Chuck Schumer—distributed a discussion draft of the Cannabis Administration and Opportunity Act, a major bill promising sweeping reforms of cannabis regulation at the federal level, notably descheduling the substance under the Controlled Substances Act. The senators’ offices invited public comment from stakeholders. On

Earlier this month, the FDA released a seven-page plan to accelerate its research into the safety of cannabis-derived products. The plan follows two reports to Congress last year (which the Perkins Coie Cannabis Industry Group has previously written about here and here) on the safety and labeling of products containing cannabidiol (CBD) and a public statement from outgoing FDA leadership in early 2021 seeking better data for a better understanding of CBD safety. For those in the industry hoping that this latest FDA announcement is the agency’s long-awaited CBD enforcement guidance, the wait continues. Instead, the FDA recognizes that “the growth of the [cannabis-derived product] market continues to outpace the growth in the science and our understanding of the public health implications of these products.”

Before issuing new rulemaking and guidance, the FDA’s new data acceleration plan notes that the agency “needs a better understanding of the quality and safety systems that are currently in place across the overall supply chain from origin, manufacturing, and distribution to consumer usage” with regard to products derived from cannabis. According to the agency, the market for these products is “fragmented and dynamic” “with hundreds of small manufacturers selling products online,” and is “rife with potential quality and safety concerns.”
Continue Reading FDA Releases Plan to Obtain Data Regarding Cannabis-Derived Product Usage & Safety


State Attorneys General (AGs) play a central role in enforcing cannabis laws and protecting consumers. As legalization continues to sweep the country, the interplay between state and federal law demands particular attention. In this edition of The 411 on 420, Perkins Coie senior counsel Andrew Kline discusses the role of the State AGs with Austin

Millions of Americans are utilizing medical cannabis and psilocybin to treat specific medical conditions each day. However, scientific and medical research lags in the U.S. lags behind other nations. Dr. Stephen M. Dahmer, Chief Medical Officer at Vireo Health, and Betty Aldworth, Director of Communications and Events at the Multidisciplinary Association for Psychedelic Studies (MAPS)

Last week, Senators Schumer (D-NY), Booker (D-NJ), and Wyden (D-OR) circulated a discussion draft of the Cannabis Administration and Opportunity Act, a legislative proposal to deschedule and legalize cannabis.  In related statements to the Senate, Senator Schumer emphasized that cannabis legislation will be prioritized during this Congress, stating “it’s time to end the federal prohibition on marijuana [a]nd as majority leader, I am going to push this issue forward and make it a priority.”

While there is much to explore in the bill’s 163 pages, here are five immediate takeaways for the cannabis industry.
Continue Reading Senators Propose Cannabis Descheduling Plan: Five Takeaways for The Cannabis Industry

It is well known that the varying state regulations for cannabis give this industry a complex legal landscape.  Nowhere is that more apparent than in the state regulations related to cannabis packaging and labeling.  Perkins Coie senior counsel Andrew Kline is joined by Doug Fischer, General Counsel of Greenlane, the leading global platform for the

Perkins Coie senior counsel Andrew Kline is joined by Andrew Freedman, Colorado’s first cannabis czar under Governor Hickenlooper and current Executive Director of the Coalition for Cannabis Policy, Education, and Regulation (CPEAR). Andrew’s role in developing a successful operating model for cannabis regulation and stakeholder collaboration was identified as one of the reasons for the

Most Americans are familiar with the term “THC” at this point. What they might not yet appreciate is that common nomenclature is actually referring to Delta-9-tetrahydrocannabinol or “Delta-9” THC. That’s the scientific terminology for the molecule in marijuana that’s well-known for its psychoactive properties—i.e., what causes a “high.” Delta-9 is a cannabinoid and there are hundreds of different cannabinoids within any given cannabis plant.
Continue Reading Delta-8: A New Low in Highs

On March 3, 2021, Perkins Coie partner Barak Cohen moderated a panel to discuss the future of the cannabis industry. Panelists included Michelle Rutter Friberg, Deputy Director of Government Relations at the National Cannabis Industry Association, Steve Hawkins, Executive Director of the Marijuana Policy Project, Yoko Miyashita, Chief Executive Officer of Leafly, and Andrew Kline,